Earnings Insights · Boston Scientific (BSX) · Q3 FY2026

Boston Scientific (BSX) Q3 FY2026: Boston Scientific Q3 2026 Earnings: Cyberattack and Rhythm-Management Pressures Reset 2027 Outlook

By AlgovestIQ ResearchPublished

Share

Read Boston Scientific’s results announcement (Form 8-K, filed Oct 28, 2026)

Key earnings findings

Boston Scientific (BSX) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. Boston Scientific reported Q3 FY2026 revenue of $5.14B against the $5.09B analyst estimate, a 1.0% beat, and EPS of $0.73 against the $0.73 analyst estimate, a 0.4% beat.
  2. BSX closed at $42.43 on Oct 28, 2026, down 5.8% from $45.06 on Oct 27, 2026, the last close before the results were released.
  3. Boston Scientific reported third-quarter revenue of $5.138B, up 1.5% year over year, while GAAP EPS fell to $0.40 from $0.51 and adjusted EPS declined to $0.73 from $0.75.

Sources: Boston Scientific results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did Boston Scientific beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$5.14B
$5.09B
+1.0%
EPS
$0.73
$0.73
+0.4%
  • EPS has beaten the estimate in all 8 of the most recent reported quarters on record.
  • Revenue surprise across the last 8 reported quarters has ranged from 0.1% to 3.4%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

Boston Scientific reported third-quarter revenue of $5.138B, up 1.5% year over year, while GAAP EPS fell to $0.40 from $0.51 and adjusted EPS declined to $0.73 from $0.75. The quarter was disrupted by an August cybersecurity incident that management estimates reduced organic growth by roughly 300 basis points and adjusted EPS by $0.07.

The more consequential issue extends beyond the outage. Boston Scientific now expects declining sales in the fourth quarter and said it will be challenged to grow revenue or adjusted EPS in 2027, excluding its pending Penumbra acquisition, as electrophysiology, WATCHMAN and China pricing pressure weigh on results. Management’s case for a return to stronger growth rests on product launches, cost restructuring and an expected improvement in its Rhythm Solutions businesses beginning in 2028.

Earnings Snapshot

MetricReportedChange
Net sales$5.138BUp 1.5%
Organic net sales growth1.5%—
GAAP diluted EPS$0.40Down from $0.51
Adjusted EPS$0.73Down from $0.75
GAAP net income attributable to common stockholders$582MDown from $755M
MedSurg sales$1.733BUp 0.6% reported; up 0.7% organic
Cardiovascular sales$3.406BUp 1.9% reported and organic
U.S. sales$3.309BUp 0.5%
EMEA sales$829MUp 4.4% reported; up 6.1% operational
APAC sales$797MDown 0.6% reported; down 1.1% operational
LACA sales$203MUp 16.0% reported; up 10.5% operational
Free cash flow$867M—
Cash on hand$690M—

The Bigger Story

The cybersecurity incident clearly hurt third-quarter operations, but it also exposed a weaker underlying growth profile than investors had become accustomed to from Boston Scientific. The eight-business-day interruption prevented the company from manufacturing and shipping product globally, reducing quarterly revenue by an estimated $150M. Operations were restored by September 8, according to management.

However, the company’s outlook suggests the disruption is not the sole problem. Management said the electrophysiology, or EP, and WATCHMAN franchises are now weighing on companywide growth after several years of outsized contributions. Boston Scientific also expects China pricing pressure to continue into 2027.

The company characterized 2027 as the trough of this cycle, with revenue and adjusted EPS potentially flat or worse excluding Penumbra. That is a meaningful reset for a business that had been growing above its weighted average market growth rate, or WAMGR, in recent years. Management expects a more favorable launch cadence, anniversary effects and restructuring savings to support improvement in 2028, with further acceleration anticipated in 2029.

Revenue and Operating Performance

Third-quarter sales increased 1.5% on a reported, operational and organic basis, as currency and acquisition effects were neutral. This was below Boston Scientific’s prior organic-growth outlook of 3% to 5%, primarily because of the cybersecurity event.

The disruption had a broad effect, although performance also varied materially by business line.

Cardiovascular revenue grew 1.9% to $3.406B. Within the segment, Interventional Cardiology and Vascular Therapies grew 12%, led by 19% growth in Interventional Cardiology. Management cited continued strength in imaging and drug-eluting technologies, including its AGENT drug-coated balloon, which has now been used to treat more than 400,000 patients.

Vascular Therapies grew just 1%, affected by the cyber incident and supply constraints in TCAR. Management expects TCAR supply to improve during the fourth quarter and to be fully resolved early next year. Interventional Oncology and Embolization grew 5%, with cancer therapies partially offset by supply constraints expected to resolve in early 2027.

Cardiac Rhythm Management declined 2%, partly because the outage complicated use and activation of technologies that rely on remote monitoring. The Diagnostics franchise grew at a high-single-digit rate, but low-voltage and high-voltage businesses declined.

MedSurg revenue rose only 0.7% organically to $1.733B. Neuromodulation was the notable bright spot, with 13% growth led by pain-management products and Nalu peripheral nerve stimulation technology. Urology declined 3%, reflecting cyber disruption and pricing pressure in China. Endoscopy declined 1%, affected by China’s volume-based procurement pricing program and the cyber incident, though management said underlying demand remained strong, particularly for the Axios franchise.

Regional trends reinforced the uneven picture. U.S. sales increased just 0.5%, held back by Interventional Cardiology, Endoscopy and Neuromodulation-related disruption. EMEA grew 6.1% operationally, aided in part by an easier comparison against a prior-year enterprise-resource-planning system implementation. APAC declined 1.1% operationally as China pricing pressure compounded the cyber impact. LACA grew 10.5% operationally, though it remains a relatively small contributor.

Profitability and Margins

The cyber event had a disproportionate effect on profitability because the shipment interruption reduced manufacturing absorption and created incremental operating costs.

Adjusted gross margin fell 300 basis points year over year to 68.0%, primarily due to unfavorable manufacturing absorption during the disruption. Adjusted operating margin declined 150 basis points to 26.5%. On a GAAP basis, operating margin was 16.1%, with reported operating income falling to $828M from $1.048B.

GAAP EPS fell 22% to $0.40. Adjusted EPS fell 3% to $0.73, including an estimated $0.07 hit from the cyber incident. The adjusted figure excludes amortization, acquisition-related items, restructuring charges, litigation-related costs and other specified items.

Reported operating expenses included an $81M litigation-related charge, largely tied to certain product-liability cases. The company also recorded $63M of restructuring-related net charges and $39M of intangible asset impairment charges.

Boston Scientific expects full-year adjusted gross margin to be below 2025 levels, citing a less favorable product mix, investment in global supply chain and quality systems, and the cyber incident. This framing matters because the company’s 2027 earnings outlook is constrained not only by sales pressure but also by mix, China pricing and ongoing investment requirements.

Demand, Customers and Pricing

The main demand concern remains WATCHMAN, Boston Scientific’s left atrial appendage closure franchise. U.S. WATCHMAN sales declined 7% during the quarter, with standalone procedures down by a high-teens percentage while concomitant procedures grew roughly 35%. International sales grew 4%.

Management attributed the broader left atrial appendage closure market slowdown primarily to changes in patient identification and referral patterns as physicians evaluate newer clinical evidence. The company has increased medical education efforts and added dedicated commercial resources, but it does not expect a near-term recovery. For the fourth quarter, management expects no improvement in U.S. standalone procedure trends and slower growth in concomitant procedures against a high prior-year comparison.

EP sales fell 5%, including an 8% decline in the U.S. and 2% international growth. Management estimated that the cyber incident accounted for roughly half of the business’s quarterly shortfall, particularly internationally. Still, it also expects continuing market-share erosion in pulsed field ablation until the expected launch of FARAWAVE Ultra in early 2028.

China is a second recurring pressure point. Management said pricing dynamics have become more challenging as volume-based procurement and other actions affect multiple businesses. It expects China growth to moderate to the single digits and anticipates additional pricing headwinds in 2027, particularly in Endoscopy and Urology.

What is Boston Scientific’s guidance for Q4 and full-year 2026?

Boston Scientific expects fourth-quarter 2026 reported and organic sales to decline by approximately 3.0% to 1.0% year over year. Management expects adjusted EPS of $0.77 to $0.79.

The fourth-quarter outlook includes a projected 200- to 300-basis-point headwind from the cybersecurity incident. Customers increased ordering after operations resumed in late September to replenish inventory, and management expects those elevated customer inventory levels to normalize during the fourth quarter. It estimates a resulting fourth-quarter EPS impact of roughly $0.04 to $0.05.

For full-year 2026, the company now expects:

  • Reported sales growth of approximately 4.25%
  • Organic sales growth of approximately 3.75%
  • Adjusted EPS of $3.16 to $3.18
  • Adjusted operating margin of approximately 27.6%
  • Adjusted tax rate of approximately 12%
  • Free cash flow of approximately $3.6B

Management also said that, excluding Penumbra, it expects the business dynamics evident in the fourth-quarter outlook to persist into 2027. It therefore expects to be challenged to grow both revenue and adjusted EPS next year.

Balance Sheet, Cash Flow and Capital

Boston Scientific generated $867M of free cash flow in the third quarter, consisting of $1.05B in operating cash flow less $180M in net capital expenditures. The company ended the quarter with $690M of cash and a gross debt leverage ratio of 1.9x.

Capital allocation remains focused on strategic tuck-in acquisitions and opportunistic share repurchases. The pending Penumbra acquisition is expected to close in early 2027, subject to remaining regulatory clearances. Management did not update its initial expected dilution estimate of $0.06 to $0.08 per share, but said higher interest rates since the deal announcement will increase financing costs and could add to dilution.

The company also entered a funding arrangement with Blackstone Life Sciences for its Vitalist circulatory-support program. Blackstone’s funding will reduce R&D expense as related costs are incurred; starting in 2030, it may receive a return on funds invested and royalties tied to Vitalist sales if milestones are met. The agreement preserves development of the program while reducing Boston Scientific’s upfront funding burden.

What Investors Should Watch

1. Cyber recovery and fourth-quarter revenue normalization

The immediate test is whether the anticipated 200- to 300-basis-point cyber-related headwind is limited to fourth-quarter inventory normalization. A clean recovery in manufacturing, shipments and customer inventory levels would remove a major temporary drag, though it would not solve the underlying EP and WATCHMAN challenges.

2. WATCHMAN procedure trends

WATCHMAN’s U.S. standalone procedure decline is central to the near-term growth outlook. Investors should monitor whether education, sales-force investment and potential label changes improve referral patterns, especially as a new competitor is expected to enter in 2027.

3. EP market share and product timing

Management expects continued EP share erosion until FARAWAVE Ultra launches in early 2028. The timing and execution of 2D ICE in the second half of 2027, FARAWAVE Ultra and the later FARAFLEX launch will determine whether the franchise can regain momentum.

4. China pricing and MedSurg recovery

China volume-based procurement pressure is likely to weigh on 2027, particularly in Endoscopy and Urology. Investors should also watch whether new stone-management products and a rebuilt commercial organization improve Urology from its current negative growth profile.

5. Restructuring savings and Penumbra financing

Management expects more than $500M of restructuring savings over three years, with more than half expected by the end of 2027. Realizing those savings while maintaining investment in product launches will be important for the 2028 margin outlook. Penumbra’s closing timing, financing cost and eventual earnings dilution also remain relevant.

AlgovestIQ Takeaway

Boston Scientific’s third quarter was weak by the company’s recent standards, and the cyberattack was a clear operational setback. It reduced revenue growth, pressured gross margin and created a fourth-quarter inventory normalization issue. The company has restored operations, and its cash generation and leverage remain supportive.

Yet the larger investment issue is the shift in Boston Scientific’s growth engine. EP and WATCHMAN, previously major contributors, are now facing competition, market-share pressure and slower procedure growth. China pricing adds another headwind, while Urology and some MedSurg businesses require operational improvement.

Management’s 2028 recovery thesis is plausible but depends on several moving parts: restoring growth in Rhythm Solutions, executing a delayed product pipeline, stabilizing WATCHMAN demand, realizing restructuring savings and integrating Penumbra. The company’s stronger franchises, including Interventional Cardiology, Neuromodulation and oncology-related therapies, provide some offset, but they are not currently sufficient to overcome the pressure in EP and WATCHMAN.

The central question is whether 2027 proves to be a temporary trough or the start of a more prolonged period of below-market growth. Evidence of improving procedure trends, disciplined cost execution, resolved supply constraints and on-time launches would support management’s case. Continued share losses in EP, further WATCHMAN deterioration, deeper China pricing pressure or additional pipeline delays would weaken it.

How did BSX stock react?

BSX closed at $42.43 on Oct 28, 2026, down 5.8% from $45.06 on Oct 27, 2026, the last close before the results were released.

SessionCloseChange
Oct 27, 2026 (before release)$45.06—
Oct 28, 2026$42.43-5.8%
Oct 29, 2026$42.69-5.3%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: Boston Scientific Q3 FY2026 earnings call transcript, as of Oct 28, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: Boston Scientific Form 8-K, Item 2.02 (SEC EDGAR), as of Oct 28, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Oct 28, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Every reported figure is checked against Boston Scientific's earnings release and call transcript before publication. Not investment advice.